Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1147-1152

  Koutroubakis, Ioannis E ^a   Theodoropoulou, Angeliki ^a   Xidakis, Costas ^a   Sfiridaki, Aekaterini ^b   Notas, George ^a   Kolios, George ^a   Kouroumalis, Elias A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Venizelion General Hospital   (Greece)

Author keywords

Crohn's disease; p selectin; Soluble CD40 ligand; Thrombosis; Ulcerative colitis

Indexed keywords

CD40 LIGAND; PADGEM PROTEIN; PROCOAGULANT; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE POOR PLASMA; ULCERATIVE COLITIS;

ADULT; ANTITHROMBIN III; BIOLOGICAL MARKERS; CD40 LIGAND; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLATELET COUNT; PROTHROMBIN; SOLUBILITY; THROMBOEMBOLISM;

EID: 8444247902     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00011     Document Type: Article

References (36)

1. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61:140-145.
2. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35:619-623.
3. Koutroubakis IE. Unraveling the mechanisms of thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96:1325-1327.
4. Hayat M, Ariens RA, Moayyedi P, Grant PJ, O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14:249-256.
5. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14:413-418.
6. Wakefield AJ, Sawyerr AM, Dhillon RP, Pittilo RM, Rowles PM, Lewis AAM, et al. Pathogenesis of Crohn's disease. Lancet 1989; 2:1057-1062.
7. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100:1279-1287.
8. Datta SK, Kalled SL. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 1997; 40:1735-1745.
9. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
10. Sawada-Hase N, Kiyohara T, Miyagawa J, Ueyama H, Nishibayashi H, Murayama Y, et al. An increased number of CD40-high monocytes in patients with Crohn's disease. Am J Gastroenterol 2000; 95:1516-1523.
11. Battaglia E, Biancone L, Resegotti A, Emanuelli G, Fronda GR, Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol 1999; 94:3279-3284.
12. Liu Z, Colpaert S, D'Haens GR, Kasran A, de Boer M, Rutgeerts P, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999; 163:4049-4057.
13. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis 2003; 18:142-147.
14. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52:1435-1441.
15. Liu Z, Geboes K, Colpaert S, Overbergh L, Mathieu C, Heremans H, et al. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol 2000; 164:6005-6014.
16. De Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, Bhan AK, et al. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 2000; 119:715-723.
17. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000; 97:6930-6932.
18. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106:896-899.
19. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92:1041-1048.
20. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80:1008-1014.
21. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nature Med 2002; 8:247-252.
22. Chamouard P, Grunebaum L, Wiesel ML, Frey PL, Wittersheim C, Sapin R, et al. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7:1183-1188.
23. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83:1535-1541.
24. Goke M, Hoffmann JC, Evers J, Kruger H, Manns MP. Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J Gastroenterol 1997; 32:480-486.
25. Schurmann GM, Bishop AE, Facer P, Vecchio M, Lee JC, Rampton DS, et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995; 36:411-418.
26. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24(suppl):2-6.
27. Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
28. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
29. Novacek G, Kapiotis S, Moser G, Speiser W, Gangl A, Vogelsang H. No evidence of activated blood coagulation in Crohn's disease. Eur J Gastroenterol Hepatol 1997; 9:963-967.
30. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999; 42:871-881.
31. Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K. Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clin Rheumatol 2003; 22:37-39.
32. Mellembakken JR, Solum NO, Ueland T, Videm V, Aukrust P. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia - possible role of platelet activation. Thromb Haemost 2001; 86:1272-1276.
33. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106:399-402.
34. Heschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-1111.
35. Henn V, Slupsky JR, Grafe M, Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591-594.
36. Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003; 124:1249-1265.